These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28755053)

  • 1. Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates.
    Landis MS; Bhattachar S; Yazdanian M; Morrison J
    AAPS PharmSciTech; 2018 Jan; 19(1):1-10. PubMed ID: 28755053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational prediction of formulation strategies for beyond-rule-of-5 compounds.
    Bergström CAS; Charman WN; Porter CJH
    Adv Drug Deliv Rev; 2016 Jun; 101():6-21. PubMed ID: 26928657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in Translational Development of Pharmaceutical Cocrystals.
    Kale DP; Zode SS; Bansal AK
    J Pharm Sci; 2017 Feb; 106(2):457-470. PubMed ID: 27914793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies to address low drug solubility in discovery and development.
    Williams HD; Trevaskis NL; Charman SA; Shanker RM; Charman WN; Pouton CW; Porter CJ
    Pharmacol Rev; 2013 Jan; 65(1):315-499. PubMed ID: 23383426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
    Saxena V; Panicucci R; Joshi Y; Garad S
    J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Selection of Bio-Enabling Oral Drug Formulations - A PEARRL Commentary.
    Kuentz M; Holm R; Kronseder C; Saal C; Griffin BT
    J Pharm Sci; 2021 May; 110(5):1921-1930. PubMed ID: 33609523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing drug discovery: a pharmaceutics perspective.
    Kwong E
    J Pharm Sci; 2015 Mar; 104(3):865-71. PubMed ID: 25482223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the development scientist in compound lead selection and optimization.
    Venkatesh S; Lipper RA
    J Pharm Sci; 2000 Feb; 89(2):145-54. PubMed ID: 10688744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.